Navigation Links
Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
Date:1/8/2009

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on an
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
2. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
3. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
5. Northwest Secures US$4.0 Million in Debt Financing
6. Nikon Instruments Opens New Imaging Center at Northwestern University
7. Northwestern chemist investigates lost reds in Homer painting
8. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
9. Northwestern chemists take gold, mass-produce Beijing Olympic logo
10. Northwest Secures US$1.0 Million Debt Financing
11. Northwest Secures US$1.65 Million Debt Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...v. 5 Imagenetix, Inc. (O...liam Spencer, President and CEO of Imagenetix, wil...ual LD MICRO Conference on Thursday, December 3rd,.... ,, About LD MICRO ,, LD MICRO is a by-invi...g undervalued companies in the micro-cap space. Si...
(Date:11/5/2009)...ll on Thursday, November 5, 2009 at 4:30 p.m. East...PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals,...I ) today reported unaudited financial results for... 30, 2009 and reviewed the Company,s highlights fo...onsolidated results reflect the operations of Onco...
(Date:11/5/2009)...., Nov. 5 BioSpecifics T...tical company developing first-in-class collagenas...sults for the third quarter ended September 30, 20...mber of this year, the FDA,s Arthritis Advisory Co..., the approval of XIAFLEX(TM) for the treatment of...
(Date:11/5/2009)...exas, Nov. 5 Wound Manag...that it has entered into a Letter of Intent to pur...lth Technologies, Inc. (OTC Bulletin Board: VHGI)....in cash and debt, 4,000,000 shares of WNDM and a r... the Veriscrip technology being acquired from VHGI...
Breaking Biology Technology:Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
...ewswire-FirstCall/ - Neptune Technologies & Bi...NTB) provides an update on business activities reg...Sales and Distribution Update, - Neptune expand... of two, additional marketing and sales execu...ckgrounds in the nutraceutical and functional food...
...(May 4, 2009): Uveitis, or inflammation within the... of visual loss roughly comparable to that caused ...ational Phase 3 program in uveitis, the LUMINATE t...e ability of LX211 (LUVENIQ, voclosporin oral caps...lammation. Additionally, in patients who are disco...
... Novavax, Inc. (Nasdaq: NVAX ) today announced ...al results in a press release to be issued after 8...Company will hold an investor conference call to d... Time on Friday, May 8, 2009. The call will be hos...er Dr. Rahul Singhvi and other members of senior m...
Other Biology Technology:Neptune Product and Distribution Update 2Neptune Product and Distribution Update 3Neptune Product and Distribution Update 4First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 2First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 3First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 4Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call 2
(Date:11/4/2009)... Long Beach and Riverside are responsible for a si...ma, and the true impact of air pollution and ship ...mated, according to researchers at the University ...h appears in an online edition of the American Jo...nt of all childhood asthma cases in Long Beach and...
(Date:11/4/2009)... the DNA codes, or genomes, of the famed fugu (or ...ome 10K Project, an international effort to build ...0 species of animals for conducting comparative st...d. , Participating in The Genome 10K project, de...ssue of the Journal of Heredity , are 70 leading ...
(Date:11/4/2009)...irstCall/ -- Quest Diagnostics Incorporated (NYSE:...c testing, information and services, announced tha...income from continuing operations rose to $192 mil...n, or $0.81 per diluted share, for the third quart...duced by a $0.03 per share charge associated with ...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Low 53464 1Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Low 53464 2Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Low 53464 3New Surgical Device Revolutionizes Face Lifts Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time Less Pain and Few 53461 1New Surgical Device Revolutionizes Face Lifts Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time Less Pain and Few 53461 2New Surgical Device Revolutionizes Face Lifts Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time Less Pain and Few 53461 3MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 1MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 2MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 3MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 4MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 5MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 6MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 7
... where and how some plant seeds store iron, a valu...he iron content of plants. Their research helps ad... malnutrition in humans. , The team found that iro...he seed of Arabidopsis, a model plant used in rese..., a plant cell,s central storage site. The researc...
...oxycycline effectively treats a type of lymphoma a... study in the October 4 issue of the Journal of ...lymphoma of the MALT-type (OAL) is a kind of cance...ten fatal, but its symptoms can compromise a patie...an association between OAL and infection with the ...
...nia Bioinformatics Institute and Duke University M...ppears to play an important role in the developmen...assicicola, a destructive fungal pathogen that cau... crops worldwide, results in considerable leaf los...anola, cabbage and broccoli. Sensitivity to spore...
Other Biology News:Plant studies reveal how, where seeds store iron 2Tearing down the fungal cell wall 2Tearing down the fungal cell wall 3
Bulk Enzymes/Bulk Proteins from Molecular Biology Resources
...rom balances and scales with RS232 ports and sends...f you can type the weight into the program, Balanc...mple to use parser extracts required data , Add da...llect data at timed intervals , Keyboard macros au...
Rabbit Anti-Human Prolactin Releasing Hormone Receptor (GPR10) Polyclonal Antibody, Unconjugated from IMGENEX
...ance data collection and automation that is contro...h Microsoft Excel , Pre-configured library of int...s , New balances can be added and configured by th...o one spreadsheet , Allows for multi-tasking dur...
Biology Products: